0001193125-26-213380
SEC filingALX Oncology reported Q1 2026 GAAP net loss of $17.9 million ($0.17 per share), a $12.8 million improvement year-over-year, driven by reduced R&D and G&A expenses following workforce reduction and clinical strategy refinement; cash stood at $169.1 million as of March 31, 2026, sufficient to fund operations into H1 2028.
ALX Oncology’s Q1 2026 financial results reflect a deliberate strategic pivot toward cost efficiency and biomarker-driven clinical execution. The $12.8 million YoY reduction in net loss — from $30.8 million to $17.9 million — was primarily driven by a $10.3 million decline in R&D expenses and a $2.6 million drop in G&A costs, both attributable to the early-2025 workforce reduction and refined clinical development strategy that reduced the number of active trials and prioritized high-potential assets. Management explicitly tied the improved financial posture to these operational decisions, noting the strengthened balance sheet supports delivery of upcoming clinical milestones. Cash of $169.1 million as of March 31, 2026 — up sharply from $48.3 million at year-end 2025 — resulted from the February 2026 equity offering that generated $140.4 million in net proceeds, extending the company’s runway to H1 2028. Clinically, the highlight was the ESMO Breast Cancer 2026 presentation of evorpacept + zanidatamab data, which demonstrated compelling, durable responses specifically in the biomarker-selected cohort (ccHER2-positive/high-CD47), reinforcing the CD47-selection hypothesis across tumor types and de-risking the ongoing ASPEN-09-Breast Phase 2 trial. With no forward-looking financial guidance disclosed, investor focus shifts squarely to the mid-2027 topline readout from ASPEN-09-Breast and the 2H 2026 safety data from the ALX2004 Phase 1 trial — both now positioned as near-term value inflection points supported by solid liquidity and disciplined execution.